Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819891 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Moderately to Severely Active Crohn's Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
- 20
- Study locations
NCT06819891 is a Phase 3 study of Moderately to Severely Active Crohn's Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 425 participants, above the 325-participant average among 3 other Moderately to Severely Active Crohn's Disease trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06819891, a Phase 3 study of Moderately to Severely Active Crohn's Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Afimkibart
Study Locations (20)
Florida
- J&A Clinical Research - Doral
- Homestead Associates in Research, Inc. - Miami
- Allied Biomedical Research Institute, Inc - Miami
- Rejuvaline Medical Research - Miami
- Miami Beach Clinical Research Center - Miami Beach
- Eminat Research Group - Miramar
- Digestive and Liver Center of Florida - Orlando
- Advanced Medical Research Center - Port Orange
- Santos Research Center, CORP - Tampa
California
- Om Research LLC - Lancaster
- Hoag Memorial Hospital Presbyterian;Hoag Center for Research and Education - Newport Beach
- Empire Clinical Research - Pomona
- Stanford Medicine Outpatient Center - Redwood City
- Amicis Research Center - Santa Clarita
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
- Louisiana Research Center - GastroIntestinal Associates - Shreveport
Arizona
- Sun City Clinical Research - Glendale
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Illinois
- The University of Chicago - Chicago
Kentucky
- Robley Rex VA Medical Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2033-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06819891
The ClinicalTrials.gov registry entry for NCT06819891 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 325-participant average among 3 other Moderately to Severely Active Crohn's Disease trials with a reported enrollment target (31% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderately to Severely Active Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06819891 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06819891 about?
NCT06819891 is a clinical study titled "A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease". This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
What is the current status of trial NCT06819891?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2025-05-12. Estimated completion is 2033-04-30.
What conditions does trial NCT06819891 study?
This clinical trial studies the following conditions: Moderately to Severely Active Crohn's Disease.
What interventions are being tested in trial NCT06819891?
The interventions under investigation include: Placebo (DRUG), Afimkibart (DRUG).
Who is sponsoring clinical trial NCT06819891?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819891 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderately to Severely Active Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED · Phase 3
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.